Digital health company, ResApp Health Ltd (ASX:RAP), is developing smartphone apps which diagnose and manage respiratory diseases – including pneumonia, asthma and bronchitis.
The company says it has shipped smartphones to a “leading global humanitarian organisation” for the purpose of field-testing its diagnostic app. ResApp has not revealed who this humanitarian organisation is just yet.
ResApp says the field evaluation is a precursor to a large-scale multi country study of the system’s ability to diagnose respiratory disease.
ResApp says this field trial will generate additional clinical evidence, and garner an in-depth understanding of the local conditions so that the company can optimise a product for essential medical personnel working in very challenging environments.
ResApp reported a net loss of $3.2 million at 30 June 2016.